Trillium Therapeutics Statistics Share Statistics Trillium Therapeutics has 0
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding n/a Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) n/a Shares Floating n/a Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 6M, so 0% of the outstanding
shares have been sold short.
Short Interest 6M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 4.69
Valuation Ratios The PE ratio is -20.76 and the forward
PE ratio is null.
Trillium Therapeutics's PEG ratio is
0.36.
PE Ratio -20.76 Forward PE n/a PS Ratio 8324.29 Forward PS n/a PB Ratio 4.42 P/FCF Ratio -54.19 PEG Ratio 0.36
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Trillium Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 13.94,
with a Debt / Equity ratio of 0.
Current Ratio 13.94 Quick Ratio 13.94 Debt / Equity 0 Debt / EBITDA -0.01 Debt / FCF -0.04 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $4.48K Profits Per Employee $-1.8M Employee Count 33 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 102K Effective Tax Rate -0.17%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.9, so Trillium Therapeutics's
price volatility has been higher than the market average.
Beta 1.9 52-Week Price Change n/a 50-Day Moving Average n/a 200-Day Moving Average n/a Relative Strength Index (RSI) n/a Average Volume (20 Days) 1,982,854
Income Statement In the last 12 months, Trillium Therapeutics had revenue of 148K
and earned -59.35M
in profits. Earnings per share was -0.71.
Revenue 148K Gross Profit 148 Operating Income -61.45M Net Income -59.35M EBITDA -58.65M EBIT n/a Earnings Per Share (EPS) -0.71
Full Income Statement Balance Sheet The company has 247.6M in cash and 831K in
debt, giving a net cash position of 246.77M.
Cash & Cash Equivalents 247.6M Total Debt 831K Net Cash 246.77M Retained Earnings -249.38M Total Assets n/a Working Capital n/a
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -22.73M
and capital expenditures 0, giving a free cash flow of -22.73M.
Operating Cash Flow -22.73M Capital Expenditures n/a Free Cash Flow -22.73M FCF Per Share -0.27
Full Cash Flow Statement Margins Gross margin is 0.1%, with operating and profit margins of -41523.65% and -40098.65%.
Gross Margin 0.1% Operating Margin -41523.65% Pretax Margin -40029.73% Profit Margin -40098.65% EBITDA Margin -39630.41% EBIT Margin -41523.65% FCF Margin -15360.14%
Dividends & Yields TRIL does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for TRIL.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 20, 2014. It was a
backward
split with a ratio of 1:30.
Last Split Date Nov 20, 2014 Split Type backward Split Ratio 1:30
Scores Altman Z-Score n/a Piotroski F-Score n/a
